Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells

J Control Release. 2007 Nov 6;123(2):164-71. doi: 10.1016/j.jconrel.2007.08.002. Epub 2007 Aug 15.

Abstract

Targeted adenoviral gene delivery using human epidermal growth factor receptor 2 (HER2/neu) is one of the promising strategies for enhancing the transduction efficacy of PEGylated adenovirus (PEG-ADV). The viral capsid of adenovirus carrying the green fluorescent protein (GFP) was conjugated with bifunctional polyethylene glycol (PEG). The surface of PEG-ADV was then further conjugated with anti-HER2/neu monoclonal antibody (MAb), Herceptin (Trastuzumab; HER) to grant HER2/neu over-expressed breast cancer cells specific targeting. The PEG-ADV and Herceptin immobilized PEG-ADV (HER-PEG-ADV) extents of retargeting were evaluated, as compared to those of naked ADV. In summary, HER-PEG-ADV exhibited more enhanced level of GFP expression than PEG-ADV did for MDA-MB-435 and MDA-MB-468 cells (a HER2/neu positive cell line), but not for a HER2/neu deficient U251N cells. PEGylated ADV significantly reduced innate immune response likewise, as judged from the amount of interleukin 6 released from macrophage cells. Consequently, this study suggests that HER-PEG-ADV conjugates enable ADV to become more potential therapeutic tools through overcoming the limitation of ADV against immune system and non-specificity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics*
  • Adenoviridae / immunology
  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / therapy*
  • Cell Line, Tumor
  • Chromatography, Liquid
  • Feasibility Studies
  • Female
  • Flow Cytometry
  • Gene Expression Regulation, Neoplastic
  • Genes, Reporter
  • Genetic Therapy / methods*
  • Genetic Vectors* / immunology
  • Green Fluorescent Proteins / genetics
  • Humans
  • Interleukin-6 / metabolism
  • Light
  • Macrophages / immunology
  • Macrophages / metabolism
  • Mice
  • Microscopy, Electron, Transmission
  • Polyethylene Glycols / chemistry*
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism
  • Scattering, Radiation
  • Transduction, Genetic*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Interleukin-6
  • Green Fluorescent Proteins
  • Polyethylene Glycols
  • Receptor, ErbB-2
  • Trastuzumab